Management of Resistant Post-transplant Lymphoproliferative Disorder: CAR-T Is a New Option.
Anticancer Res. 2022 Nov;42(11):5181-5186. doi: 10.21873/anticanres.16024.
Anticancer Res. 2022.
PMID: 36288856
Review.